MEXITIL Drug Patent Profile

✉ Email this page to a colleague

When do Mexitil patents expire, and what generic alternatives are available?

Mexitil is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in MEXITIL is mexiletine hydrochloride. There are five drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the mexiletine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mexitil

A generic version of MEXITIL was approved as mexiletine hydrochloride by TEVA on May 16^th, 1995.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for MEXITIL?
What are the global sales for MEXITIL?
What is Average Wholesale Price for MEXITIL?

Summary for MEXITIL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	214
Clinical Trials:	4
Patent Applications:	1,058
Formulation / Manufacturing:	see details
DailyMed Link:	MEXITIL at DailyMed

Drug patent expirations by year for MEXITIL

Recent Clinical Trials for MEXITIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts General Hospital	Phase 2
Spaulding Clinical Research LLC	Phase 1
Food and Drug Administration (FDA)	Phase 1

See all MEXITIL clinical trials

US Patents and Regulatory Information for MEXITIL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-002	Dec 30, 1985		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-003	Dec 30, 1985		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-004	Dec 30, 1985		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for MEXITIL

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-004	Dec 30, 1985	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-004	Dec 30, 1985	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-002	Dec 30, 1985	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	MEXITIL	mexiletine hydrochloride	CAPSULE;ORAL	018873-003	Dec 30, 1985	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for MEXITIL

See the table below for patents covering MEXITIL around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Austria	289075		⤷ Sign Up
Germany	1643240		⤷ Sign Up
Switzerland	516512	Verfahren zur Herstellung neuer substituierter 1-Phenoxy-2-aminopropane	⤷ Sign Up
Switzerland	509251	Verfahren zur Herstellung neuer substituierter 1-Phenoxy-2-aminoalkane	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for MEXITIL

Recent Clinical Trials for MEXITIL

Make Better Decisions: Try a trial or see plans & pricing